Toronto. December 12, 2019 – Prostate Cancer Canada and the Canadian Cancer Society (CCS) are excited to announce their intention to embark upon a strategic amalgamation that will strengthen and support cancer research, education and the needs of Canadians and their families dealing with the disease. As part of the agreement, Prostate Cancer Canada’s activities and initiatives will remain an important part of the Canadian Cancer Society.

Toronto (ON) – September 26, 2019 – New findings released today in a Prostate Cancer Canada nationwide survey suggest 1.5 million Canadian men 50+ are not seeking early prostate cancer testing through the prostate specific antigen (PSA) blood test. The survey, Men At Risk: The Prostate Cancer Testing Gap, shows while awareness about the importance of early detection is high, Canadian men 50+ are reluctant to be tested.

February 22, 2019 – TORONTO, ON – A dream came true today for Harold Mutter (ticket #19273), the lucky winner of a 2018 Acura NSX valued at more than $235,000 - the prize for Prostate Cancer Canada’s seventh Rock the Road Raffle.

Toronto, October 23, 2018 – Prostate Cancer Canada and the Movember Foundation today announced $4 million in funding to three Canadian researchers to predict how well prostate cancer will respond to treatment, based on men’s biological markers, specifically in their tumour cells and blood – opening a path to more personalized care with fewer side effects and a better chance of survival. The grants have been awarded to Dr. Tarek Bismar from the University of Calgary, Dr. Hansen He from University Health Network and Dr. Kim Chi from BC Cancer.  This research aims to determine how we can use a man’s tumour biology to offer better care to men at three critical stages of their prostate cancer journey.

Vancouver, September 25, 2018 – Research funded by Prostate Cancer Canada is preparing the way to improve quality of life for men-who-have-sex-with-men (MSM)1 in the LGBTQ2+ community.

WINNIPEG, MB (August 16, 2018) – Prostate Cancer Canada is pleased to congratulate Winnipeg-based Arnold Bros. Transport Ltd. and honour its team with the coveted “Plaid Vest” award for its outstanding efforts raising funds and awareness during the Plaid for Dad fundraiser. The group raised over $19,000, and wrapped one of its tractor-trailers in plaid to take the message to the streets.

Toronto, June 27, 2018 – Canadian researchers are leading the future of treatment for men with advanced prostate cancer in this country, with a new Prostate Cancer Canada grant funded by the Movember Foundation. The National Program on Targeted Radionuclide Therapy for Prostate Cancer focuses on radioligand therapy (RLT): a new form of treatment for men with advanced prostate cancer which cannot be cured by current methods. This coordinated, national initiative aims to accelerate access to this promising and innovative treatment for Canadian men.

TORONTO, ON – (May 8, 2018) – Plaid replaces business-casual on Friday, June 15 as hundreds of thousands of Canadians don the iconic Canadian attire all to honour dad and end prostate cancer. The nationwide Prostate Cancer Canada fundraiser and awareness campaign sees scores of workplaces and individuals changing the lives of the one in seven Canadian men who will be diagnosed with the disease.

TORONTO, CANADA (May 8, 2018) – Every day, more and more methods to detect prostate cancer are being explored, but the tried and true methods of a digital rectal examination (DRE) – where a healthcare professional inserts a gloved finger into the rectum to check for abnormalities, paired with a blood test known as the prostate-specific antigen (PSA) test – which you can get through your family doctor, are still the long-standing proven ways to save a life.

Toronto (April 19, 2018) – Findings from Canadian Prostate Cancer Genome Network (CPC-GENE) researchers and their collaborators, published today in Cell, show that the aggressiveness of an individual prostate cancer can be accurately assessed by looking at how that tumour has evolved. This information can be used to determine what type and how much treatment should be given to each patient, or if any is needed at all.